Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2352 • ACR Convergence 2025
Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update
Martin Rudwaleit¹, Irene E. van der Horst-Bruinsma², Floris A. van Gaalen³, Nigil Haroon⁴, Lianne S. Gensler⁵, Myriam Manente⁶, Chetan Prajapati⁷, Katy White⁷, Atul Deodhar⁸ and Matthew A. Brown⁹, ¹Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany, ²Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶UCB, Braine-L'Alleud, Belgium, ⁷UCB, Slough, United Kingdom, ⁸Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁹Genomics England, London, United Kingdom
Background/Purpose: Uveitis is a common extra-musculoskeletal manifestation in patients (pts) with spondyloarthritis (SpA); incidence varies with SpA type and disease duration.1–3 IL-17 has been implicated…
Abstract Number: 2373 • ACR Convergence 2025
Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study
Rocio Gonzalez Molina¹, BEATRIZ JOVEN², Marta Llanes³, Vanesa Hernandez⁴, Manuel Jose Moreno⁵, Elena Blanco⁶, Carolina Marin⁷, Lourdes Mateo⁸, Meritxell Salles Lizarzaburu⁹, Martina Steiner¹⁰, Laura Nuño¹¹, Antonio Fernández-Nebro¹², raúl Veroz González¹³, ana Urruticoechea-Arana¹⁴, Evelin Cervantes¹⁵, emilio Giner¹⁶, Lola Fernandez de la fuente Burson¹⁷, Alba Erra¹⁸, Oscar Camacho¹⁹, Elisabet Garcia²⁰, Angeles Hernandez²¹, Janire Malave²², Laia Orpinell²³, Inmaculada Ros Vilamajo²⁴, Sonia Castro²⁵, Patricia Lopez Viejo²⁶, Luis Sarabia²⁷, Rosa María García Portales²⁸, Jorge Cabezon²⁹, Puerto Moreno Gil³⁰, Francisco Maceiras³¹, Daniel Pielfort³², Sabela Diaz-Castroverde³³, Manuel Cuervas-mons³³, Jose Pinto-Tasende³⁴, Santiago Muñoz³⁵ and Julio Ramirez³⁶, ¹Hospital Reina Sofía, Murcia, Spain, ²H. Universitario ¹² Octubre, Madrid, Spain, ³H Juan Ramón Jimenez, Huelva, Spain, ⁴Hospital Universitario Canarias, Tenerife, Spain, ⁵Hospital Universitario Virgen de la Arrixaca, El Palmar Murcia, Spain, ⁶Hospital Virgen del Rocio, Sevilla, Spain, ⁷Hospital Infanta Leonor, Madrid, Madrid, Spain, ⁸Hospital Trías i Pujol, Barcelona, Catalonia, Spain, ⁹Rheumatology Department, Althaia Xarxa Assistencial Universitària Manresa Manresa (Spain)., Manresa, Spain, ¹⁰Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Madrid, Spain, ¹¹Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹²Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ¹³Rheumatology. Hospital de Mérida. Mérida, Spain., Mérida, Spain, ¹⁴Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ¹⁵Hospital Provincial de Pontevedra, Pontevedra, Spain, ¹⁶Hospital Royo Vilanova, Zaragoza, Spain, ¹⁷Hospital Quironsalud Infanta Luisa, Sevilla, Spain, ¹⁸Hospital Vall d´Hebron, Barcelona, Spain, ¹⁹Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ²⁰Hospital Mollet, Barcelona, Spain, ²¹Hospital Naval, A Coruña, Spain, ²²Hospital Virgen del Puerto, Caceres, Spain, ²³Hospital Universitari Sagrat Cor, Barcelona, Spain, ²⁴Hospital Son Llàtzer, Palma de Mallorca, Spain, ²⁵ALTHAIA Hospital Sant Joan de Deu, Barcelona, Spain, ²⁶Hospital Universitario Getafe, Getafe, Spain, ²⁷Complejo Hospitalario de Jaén, Jaén, Spain, ²⁸HOSP. UNIVERSITARIO VIRGEN DE LA VICTORIA, Malaga, Spain, ²⁹HOSP. PUNTA DE EUROPA, Algeciras, Spain, ³⁰HOSPITAL SAN PEDRO DE ALCANTARA, Caceres, Spain, ³¹HOSPITAL DO MEIXOEIRO, Vigo, Spain, ³²Hospital General Universitario de Toledo, Toledo, Spain, ³³Johnson and Johnson, Madrid, Spain, ³⁴Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain, ³⁵Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ³⁶Clinic Barcelona Hospital Universitari, Barcelona, Catalonia, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease affecting joints, entheses, skin, nails, and spine. While treatment options have expanded, TNF inhibitors (TNFis) remain the…
Abstract Number: 0405 • ACR Convergence 2025
Juvenile Psoriatic Arthritis and Enthesitis-Related Arthritis: 4-Year Results From the JUNIPERA Extension Study
Hermine Brunner¹, Ivan Foeldvari², Gerd Horneff³, Antonio Mera Varela⁴, Angelo Ravelli⁵, Sharonjeet Kaur⁶, Swapnil Suhas Dahale⁷, Ruvie Martin⁸, Daniel Lovell¹, Alberto Martini⁹ and Nicolino Ruperto¹⁰, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Hamburger Zentrum fuer Kinder und Jugendrheumatologie, Rheumatology, Hamburg, Germany, ³Asklepios Klinik, Hamburg, Germany, ⁴Rheumatology Division. Hospital Clínico Universitario de Santiago and Instituto de Investigaciones Sanitarias (IDIS), School of Medicine, Santiago de Compostela, Spain, ⁵IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷IQVIA, Mumbai, India, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Università di Genova, Genova, Italy, ¹⁰Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy
Background/Purpose: Secukinumab demonstrated efficacy and safety in patients with juvenile idiopathic arthritis (JIA), including enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), for up to…
Abstract Number: 0549 • ACR Convergence 2025
High Prevalence of Obstructive Sleep Apnea in Psoriatic Arthritis: A Polysomnography-Based Cross-Sectional Study
Suzan Attar¹, Siraj Walli², Yasser Bawazir³, Mohammad Mustafa⁴, Ayah Boudal⁵, Faris alhejailli², Ahmad Bamagoos² and Omar Kanbr², ¹King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia, ²KAU, Jeddah, Saudi Arabia, ³King Abdulaziz University, Jeddah, Saudi Arabia, ⁴Jeddah University, Jeddah, Saudi Arabia, ⁵King Abdullah Medical Complex, Jeddah, Saudi Arabia
Background/Purpose: Background: Obstructive sleep apnea (OSA) is increasingly recognized in patients with psoriatic arthritis (PsA), yet few studies have used polysomnography (PSG)—the gold-standard diagnostic method.…
Abstract Number: 0567 • ACR Convergence 2025
Sonelokimab in Biologic-Experienced Patients With Active Psoriatic Arthritis: Results From a Phase 2 Trial (ARGO) and Study Design of a Phase 3 Trial (IZAR-2) in Patients With Inadequate Response or Intolerance to Biologic TNFi, Including a Risankizumab Reference Arm
Atul Deodhar¹, Laure Gossec², Philip J. Mease³, Xenofon Baraliakos⁴, Lihi Eder⁵, Alan Kivitz⁶, Helena Marzo-Ortega⁷, Frank Behrens⁸, Ana-Maria Orbai⁹, Georg Schett¹⁰, Arthur Kavanaugh¹¹, Dennis McGonagle¹², Christopher Ritchlin¹³, Nuala Brennan¹⁴, Ben Porter-Brown¹⁴, Eva Cullen¹⁴, Matthew R. Thomas¹⁴, Marius Albulescu¹⁴, Alex Godwood¹⁴, Kristian Reich¹⁵ and Laura Coates¹⁶, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵University of Toronto, Toronto, ON, Canada, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ⁸Rheumatology, Immunology - Inflammation Medicine, University Hospital Goethe-University & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, ⁹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹¹University of California, San Diego, School of Medicine, San Diego, CA, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ¹³University of Rochester Medical Center, Canandaigua, NY, ¹⁴MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁵MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ¹⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Sonelokimab (SLK), a novel Nanobody that binds to both IL-17A and IL-17F with similarly high affinity, is designed to target difficult-to-reach sites of inflammation.…
Abstract Number: 0996 • ACR Convergence 2025
Breaking Inflammatory Pathways: ELN28, a Novel Dual TNFα/JAK Inhibitor Drug Conjugate for Chronic Inflammation
Obinna Ubah, Euan Murray, Stella Priyanka, Julia Martinez Fraile, Andrew Porter, Robert Boyd and Caroline Barelle, Elasmogen Limited, Aberdeen, United Kingdom
Background/Purpose: Despite advances in therapies for chronic autoimmune diseases such as rheumatoid arthritis (RA), significant unmet needs persist, including therapeutic ceiling effects, adverse events, and…
Abstract Number: 1415 • ACR Convergence 2025
The Association of Handedness with Radiographic Damage in Patients with Psoriatic Arthritis
Fadi Kharouf¹, Shahad Al-Matar², Virginia Carrizo Abarza³, Pankti Mehta⁴, Shangyi Gao⁵, Daniel Pereira⁶, Richard Cook⁷, Vinod Chandran⁸, Denis Poddubnyy⁹ and Dafna D. Gladman¹⁰, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²University of alberta, Edmonton, AB, Canada, ³Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁵Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁶University Health Network, Toronto, ON, Canada, ⁷University of Waterloo, Waterloo, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada
Background/Purpose: Mechanical stress is known to trigger and exacerbate psoriatic arthritis (PsA). Based on the hypothesis that biomechanical stress is greater in the dominant extremity,…
Abstract Number: 1455 • ACR Convergence 2025
Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design
Philip J. Mease¹, Laure Gossec², Atul Deodhar³, Xenofon Baraliakos⁴, Frank Behrens⁵, Joseph F Merola⁶, Lihi Eder⁷, Ana-Maria Orbai⁸, Andreas Ramming⁹, Iain McInnes¹⁰, Alexis Ogdie¹¹, Dennis McGonagle¹², Christopher Ritchlin¹³, Nuala Brennan¹⁴, Ben Porter-Brown¹⁴, Eva Cullen¹⁴, Matthew R. Thomas¹⁴, Marius Albulescu¹⁴, Alex Godwood¹⁴, Kristian Reich¹⁵ and Laura Coates¹⁶, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumatology, Immunology - Inflammation Medicine, University Hospital Goethe-University & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, ⁶Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁷University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ¹³University of Rochester Medical Center, Canandaigua, NY, ¹⁴MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁵MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ¹⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Sonelokimab (SLK), a novel Nanobody that binds to both IL-17A and IL-17F with similarly high affinity, is designed to target difficult-to-reach sites of inflammation…
Abstract Number: 1757 • ACR Convergence 2025
Skin-to-Joint Immune Cell Migration and Synovial Reprogramming in Psoriatic Arthritis Onset
Maria Gabriella Raimondo¹, Hashem Mohammadian², Mario Angeli², Vladyslav Fedorchenko², Kaiyue Huang³, Yi-Nan Li⁴, Raphael Micheroli⁵, Jörg Distler⁶, Ursula Fearon⁷, Juergen Rech², Francesco Ciccia⁸, Juan Cañete⁹, Adam Croft¹⁰, Mariola Kurowska-Stolarska¹¹, Stefano Alivernini¹², Maria Antonietta D'Agostino¹³, Georg Schett², Simon Rauber¹⁴ and Andreas Ramming¹⁵, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, ⁴University Hospital of Düsseldorf, Düsseldorf, Germany, ⁵University Hospital Zurich, Zurich, Switzerland, ⁶University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ⁷Trinity College Dublin, Dublin, Dublin, Ireland, ⁸Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy, ⁹Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ¹⁰University of Birmingham, Hagley, Stourbridge, United Kingdom, ¹¹University of Glasgow, Glasgow, ¹²Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹³Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Bayern, Germany, ¹⁵Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Psoriatic arthritis (PsA) develops in about 30% of individuals with psoriasis (PsO), highlighting a critical connection between skin and joint inflammation. However, the mechanisms…
Abstract Number: 2313 • ACR Convergence 2025
From Plaque to Plaque: Bridging Oral and Systemic Inflammation in Psoriasis and PsA
guru Vijay Chagalakondu, Vijaya prasanna Parimi and Pradeep S Anand, ESIC Medical College and Super Specilaity Hospital, hyderabad, Telangana, India
Background/Purpose: Psoriasis and psoriatic arthritis (PsA) are two chronic inflammatory conditions which have similar immunopathological mechanisms which also cause periodontal disease. The association between these…
Abstract Number: 2355 • ACR Convergence 2025
Ixekizumab Provided Rapid Improvement in Key Patient Subgroups with Psoriatic Arthritis: Findings from a Prospective Observational Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
KURT OELKE¹, Sarah Ross², Emily Edson-Heredia³, Jennifer Pustizzi⁴, Ali Sheikhi Mehrabadi⁵, Natalia Bello⁵, Frederick Murphy⁶, Shikha Singla⁷, Siba Raychaudhuri⁸, Philip J Mease⁹ and Arthur Kavanaugh¹⁰, ¹rheumatic disease center, Glendale, WI, ²Lilly, Indianapolis, IN, ³eli lilly, indianapolis, ⁴Eli Lilly, Hammonton, NJ, ⁵Eli Lilly, Indianapolis, IN, ⁶Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁷Medical College of Wisconsin, Milwaukee, WI, ⁸UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ⁹University of Washington, Seattle, WA, ¹⁰University of California, San Diego, School of Medicine, San Diego, CA

Background/Purpose: Ixekizumab (IXE) is an FDA-approved monoclonal antibody that targets interleukin-17A.Methods: Psoriatic Arthritis Real-World Study in the US (PARTUS) was a prospective, multicenter, non-interventional cohort…
Abstract Number: 2375 • ACR Convergence 2025
Ixekizumab Provided Rapid Improvements in Quality of Life and Disease Activity in Patients with Psoriatic Arthritis: Findings from a Real-World Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
KURT OELKE¹, Emily Edson-Heredia², Sarah Ross³, Jennifer Marie Pustizzi⁴, Ali Sheikhi Mehrabadi⁴, Natalia Bello⁴, Frederick Murphy⁵, Shikha Singla⁶, Siba Raychaudhuri⁷, Philip J Mease⁸ and Arthur Kavanaugh⁹, ¹rheumatic disease center, Glendale, WI, ²eli lilly, indianapolis, ³Lilly, Indianapolis, IN, ⁴Eli Lilly, Indianapolis, IN, ⁵Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁶Medical College of Wisconsin, Milwaukee, WI, ⁷UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ⁸University of Washington, Seattle, WA, ⁹University of California, San Diego, School of Medicine, San Diego, CA

Background/Purpose: Ixekizumab (IXE) is a selective interleukin-17A antagonist that has proven effective in Phase 3 and 4 clinical trials for patients with psoriatic arthritis (PsA).Methods:…
Abstract Number: 0455 • ACR Convergence 2025
Assessment of Pain Outcomes in Pooled Phase 3 Trials of a Selective, Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients With Active Psoriatic Arthritis
Lihi Eder¹, Philip J. Mease², Vibeke Strand³, Alexis Ogdie⁴, Atul Deodhar⁵, Rebecca Haberman⁶, April Armstrong⁷, Alice B. Gottlieb⁸, David Roberts⁹, Laurie Eliason¹⁰, Stefan Varga¹¹, Eleni Vritzali¹², Janice Li¹¹ and Laure Gossec¹³, ¹University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁶NYU Langone Health, New York, NY, ⁷University of California Los Angeles, Los Angeles, CA, USA, Los Angeles, CA, ⁸Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁹Bristol Myers Squibb, Uxbridge, United Kingdom, ¹⁰Bristol Myers Squibb,, Princeton, NJ, ¹¹Bristol Myers Squibb, Princeton, NJ, ¹²Bristol Myers Squibb, Boudry, Switzerland, ¹³Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Patients rate pain as one of the most important aspects of psoriatic arthritis (PsA). Pain signaling involves a series of cytokines, including those downstream…
Abstract Number: 0831 • ACR Convergence 2025
Altered expression of CD11c and HLA-DR on monocyte subsets in individuals at risk of rheumatoid and psoriatic arthritis
Klára Prajzlerová¹, Olga Kryštůfková², Hana Hulejová¹, Nora Růžičková², Petra Hánová¹, Jiri Vencovsky³, Ladislav Šenolt², Jiří Štolfa² and Mária Filková², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology, Praha ⁸, Czech Republic
Background/Purpose: Preclinical phases of rheumatoid arthritis (RA), including therapeutic interventions, have been extensively studied. There is a growing focus on individuals at risk for psoriatic…
Abstract Number: 0570 • ACR Convergence 2025
Phyto- and Endo-cannabinoids Exhibit Ex Vivo Anti-Inflammatory Effects in Refractory Rheumatic inflammatory/Autoimmune Patients: Toward Personalized Cannabinoid Therapy
Gilad Halpert¹, Eri Govrin¹, Omer Gendelman¹, Abdulla Watad², Yehuda Shoenfeld¹ and Howard Amital¹, ¹Sheba Medical Center, Ramat Gan, Israel, ²Tel Hashomer Medical Center, Ramat Gan, Israel
Background/Purpose: A substantial number of patients with rheumatic inflammatory/autoimmune diseases, do not achieve adequate symptom control with current standard-of-care therapies, including biologics. The endocannabinoid system…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].